1. Molecular assessment of lymph nodes in patients with resected stage I non–small cell lung cancer: Preliminary results of a prospective study 
Steven A. Ahrendt, MD, Stephen C. Yang, MD, Li Wu, Carmen M. Roig, BSN, RN, Pamela Russell, BA, William H. Westra, MD, Jin Jen, MD, Malcolm V. Brock, MD, Richard F. Heitmiller, MD, David Sidransky, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 123, Issue 3, Pages (March 2002)
DOI: /mtc
Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

2. Figure. 1
Percentages of mutantTP53 clones in histopathologically determined negative (black bars) and histopathologically determined positive (white bars) lymph nodes from patients with NSCLC. Only 1 of 11 lymph nodes with fewer than 4.35% mutantTP53 clones (dashed line) was detected by standard light microscopy of hematoxylin and eosin–stained section.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc )
Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

3. Figure. 2
Disease-apecific survivals for patients withTP53 and/or K-ras mutations in NSCLC. Disease-specific survival in node-negative NSCLC according to both pathologic and molecular studies (dotted line) was significantly (P <.03) longer than in histopathologically determined node-positive (N1 or N2; positive by both histopathologic and molecular assays) NSCLC (heavy line). No difference in disease-specific survival was seen between patients with lymph node micrometastases according to molecular analysis alone (fine line) and patients with node-negative disease according to both pathologic and molecular studies.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc )
Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions